Rep. Gilbert Ray Cisneros, Jr. Sells Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Lantheus Holdings, Inc. (NASDAQ:LNTH). In a filing disclosed on November 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Lantheus stock on October 15th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $101.60 on Thursday. The company has a quick ratio of 3.06, a current ratio of 3.25 and a debt-to-equity ratio of 0.42. The business’s 50 day moving average is $100.30 and its two-hundred day moving average is $92.57. The company has a market cap of $6.64 billion, a P/E ratio of 25.02 and a beta of 0.01. Lantheus Holdings, Inc. has a 12 month low of $51.47 and a 12 month high of $111.86.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, November 5th. The medical equipment provider reported $1.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.45. The firm had revenue of $389.91 million for the quarter, compared to analyst estimates of $355.74 million. Lantheus had a return on equity of 29.26% and a net margin of 17.28%. The company’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.27 earnings per share. On average, equities analysts expect that Lantheus Holdings, Inc. will post 4.54 EPS for the current year.

Institutional Investors Weigh In On Lantheus

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jupiter Topco LLC acquired a new position in Lantheus in the second quarter worth $575,628,000. Assenagon Asset Management S.A. grew its stake in shares of Lantheus by 440.3% during the second quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after purchasing an additional 582,661 shares during the period. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of Lantheus by 686.1% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock worth $45,423,000 after buying an additional 522,678 shares during the period. Summit Street Capital Management LLC bought a new stake in Lantheus in the second quarter valued at approximately $44,454,000. Finally, Defilade Capital Management L.P. bought a new position in shares of Lantheus during the first quarter worth $18,917,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on LNTH shares. Mizuho cut shares of Lantheus from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $115.00 to $109.00 in a research note on Tuesday, October 13th. Leerink Partners set a $102.50 target price on shares of Lantheus in a research report on Monday, August 3rd. Brookline Capital Markets cut shares of Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. CJS Securities lowered shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research report on Tuesday, August 4th. Finally, Truist Financial cut shares of Lantheus from a “buy” rating to a “hold” rating and cut their price target for the stock from $125.00 to $102.50 in a research note on Monday, August 3rd. Three investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Lantheus currently has a consensus rating of “Hold” and an average target price of $107.44.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Lantheus Company Profile

Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology. The company’s products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.